These two injectable products expand Bioniche Pharma's growing product line

LAKE FOREST, Ill., Nov. 12 /PRNewswire/ -- Bioniche Pharma, a leading developer and manufacturer of injectable pharmaceuticals, announced today the acquisition of Duraclon® (clonidine hydrochloride injection) and Methadone Hydrochloride Injection USP from Xanodyne Pharmaceuticals, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO)

"Bioniche Pharma is very pleased to expand our product line with these injectable drugs," said Steve Thornton, Bioniche Pharma CEO. "These two products represent our commitment to expanding our product line with a combination of brand and generic drugs, which strengthens our position as a specialty injectables pharmaceutical company."

Duraclon®(clonidine hydrochloride injection) has a black box warning relating to risk of hemodynamic instability, especially hypotension and bradycardia in obstetrical, postpartum and peri-operative pain management. Methadone Hydrochloride Injection USP has black box warnings relating to peri-operative pain management and to conditions for distribution and use for the treatment of opioid addiction. Please refer to the Bioniche Pharma website for the complete prescribing information, including the boxed warnings, for these products.

About Bioniche Pharma:

Bioniche Pharma is a global manufacturer of injectable pharmaceutical products serving a variety of niche markets, with expertise in injectable hyaluronic acid products for use in orthopedics, rheumatology, urology, and dermatology. An internal development pipeline and an aggressive acquisition strategy for products fuel the company's growth. RoundTable Healthcare Partners, a private equity firm based in Lake Forest, Illinois, acquired Bioniche Pharma in February 2006. More information about Bioniche Pharma can be found at www.bionichepharma.com .

Duraclon® is a registered trademark of Astellas US LLC

SOURCE Bioniche Pharma

Back to top

RELATED LINKS
http://www.bionichepharmausa.com